The Netherlands Cancer Institute in Amsterdam was founded in 1913 by, among others, the surgeon Jacob Rotgans. The NKI, together with the Antoni van Leeuwenhoekziekenhuis, is formed into the NKI-AVL, which combines a scientific research institute with a specialized clinic focused on combating the disease cancer.

During the past decade, Netherlands Cancer Institute conducted 154 clinical trials. In the 10-year time frame, 154 clinical trials started and 21 clinical trials were completed, i.e. on average, 13.6% percent of trials that started reached the finish line to date. In the past 5 years, 73 clinical trials started and 14 clinical trials were completed. i.e. 19.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Netherlands Cancer Institute" #1 sponsor was "The Netherlands Cancer Institute" with 70 trials, followed by "European Organisation for Research and Treatment of Cancer - EORTC" with 32 trials sponsored, "Radboud University Medical Center" with 8 trials sponsored, "Bayer" with 6 trials sponsored and "Incyte Corporation" with 6 trials sponsored. Other sponsors include 118 different institutions and companies that sponsored additional 83 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Netherlands Cancer Institute" #1 collaborator was "The Netherlands Cancer Institute" with 25 trials as a collaborator, "Dutch Cancer Society" with 13 trials as a collaborator, "AstraZeneca" with 9 trials as a collaborator, "Leiden University Medical Center" with 9 trials as a collaborator and "Erasmus Medical Center" with 8 trials as a collaborator. Other collaborators include 226 different institutions and companies that were collaborators in the rest 148 trials.

According to Clinical.Site data, the most researched conditions in "Netherlands Cancer Institute" are "Breast Cancer" (18 trials), "Cancer" (9 trials), "Colorectal Cancer" (9 trials), "Prostate Cancer" (9 trials) and "Bladder Cancer" (8 trials). Many other conditions were trialed in "Netherlands Cancer Institute" in a lesser frequency.

Most popular intervention types in "Netherlands Cancer Institute" are "Drug" (161 trials), "Procedure" (38 trials), "Radiation" (37 trials), "Other" (26 trials) and "Biological" (18 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "cisplatin" (6 trials), "doxorubicin hydrochloride" (6 trials), "Cisplatin" (5 trials) and "ModraDoc006/r" (5 trials). Other intervention names were less common.

The vast majority of trials in "Netherlands Cancer Institute" are 192 trials for "All" genders, 34 trials for "Female" genders and 19 trials for "Male" genders.

Currently, there are NaN active trials in "Netherlands Cancer Institute". 4 are not yet recruiting, 62 are recruiting, 30 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 97 completed trials in Netherlands Cancer Institute, undefined suspended trials, and 18 terminated clinical trials to date.

Out of the total trials that were conducted in Netherlands Cancer Institute, 60 "Phase 1" clinical trials were conducted, 83 "Phase 2" clinical trials and 61 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 33 trials that are defined as “Not Applicable".